Enthera is a biotech company focused on developing breakthrough biologics for underserved autoimmune conditions. Their primary focus is on Type 1 Diabetes (T1D) and Inflammatory Bowel Disease (IBD). Their mission is to develop disease-modifying treatments that preserve and restore cell and organ function to reverse the effects of these conditions.

Enthera's pioneering approach targets the IGFBP3/TMEM219 pathway, a novel stem cell apoptosis pathway involved in the development and progression of autoimmune diseases. By targeting this pathway, they aim to provide safe and effective therapeutics for patients with high unmet medical needs. With a proven discovery engine, Enthera delivers libraries of monoclonal antibodies and fusion proteins that selectively inhibit the IGFBP3/TMEM219 pathway.

These inhibitors work at different stages of the pathway to prevent the binding of IGFBP3 to the TMEM219 receptor. Enthera is dedicated to treating underserved medical conditions that currently have no cure or only high failure-rate treatments. They are currently developing two clinical candidates, Ent001, their lead program, aims to preserve and restore the endogenous pancreatic beta cells compartment in T1D and restore the original intestine structure in IBD to re-establish organ function.

Backed by world-class investors such as BiovelocITA, Sofinnova Partners, JDRF, and private investors, Enthera has a strong leadership team with expertise in drug development and regulatory approvals